An aberrant sugar modification of BACE 1 blocks its lysosomal targeting in A lzheimer's disease

  • Kizuka Y
  • Kitazume S
  • Fujinawa R
  • et al.
156Citations
Citations of this article
150Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The β‐site amyloid precursor protein cleaving enzyme‐1 ( BACE 1), an essential protease for the generation of amyloid‐β (Aβ) peptide, is a major drug target for Alzheimer's disease ( AD ). However, there is a concern that inhibiting BACE 1 could also affect several physiological functions. Here, we show that BACE 1 is modified with bisecting N‐acetylglucosamine (Glc NA c), a sugar modification highly expressed in brain, and demonstrate that AD patients have higher levels of bisecting Glc NA c on BACE 1. Analysis of knockout mice lacking the biosynthetic enzyme for bisecting Glc NA c, GnT‐ III ( Mgat3 ), revealed that cleavage of Aβ‐precursor protein ( APP ) by BACE 1 is reduced in these mice, resulting in a decrease in Aβ plaques and improved cognitive function. The lack of this modification directs BACE 1 to late endosomes/lysosomes where it is less colocalized with APP , leading to accelerated lysosomal degradation. Notably, other BACE 1 substrates, CHL 1 and contactin‐2, are normally cleaved in GnT‐ III ‐deficient mice, suggesting that the effect of bisecting Glc NA c on BACE 1 is selective to APP . Considering that GnT‐ III ‐deficient mice remain healthy, GnT‐ III may be a novel and promising drug target for AD therapeutics. image Bisecting Glc NA c modification of BACE 1 by GnT‐ III is a novel regulator of BACE 1 stability. Loss of GnT‐ III curbs BACE 1‐mediated Aβ plaque generation. Hence, the bisecting Glc NA c biosynthesis pathway is a promising new target for AD therapy. Alzheimer's disease ( AD ) patients present high levels of bisecting Glc NA c modifications on BACE 1. Loss of bisecting Glc NA c reduces BACE 1‐mediated Aβ generation, leading to amelioration of AD pathology. Loss of bisecting Glc NA c reduces BACE 1– APP localization. The enzyme responsible for the biosynthesis of bisecting Glc NA c, G n T ‐ III , is therefore a potential new drug target for AD .

Cite

CITATION STYLE

APA

Kizuka, Y., Kitazume, S., Fujinawa, R., Saito, T., Iwata, N., Saido, T. C., … Taniguchi, N. (2015). An aberrant sugar modification of BACE 1 blocks its lysosomal targeting in A lzheimer’s disease. EMBO Molecular Medicine, 7(2), 175–189. https://doi.org/10.15252/emmm.201404438

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free